Dopamine D1 receptor – Glutamate receptor ionotropic, NMDA 1 heteromeric complex (D1R–GluN1) (D1R–GluN1 complex)

The Dopamine D1 receptor – Glutamate receptor ionotropic, NMDA 1 heteromeric complex (D1R–GluN1) is a functional molecular assembly formed by the direct physical interaction between the G protein-coupled dopamine D1 receptor and the GluN1 subunit of the N-methyl-D-aspartate (NMDA) receptor. This interaction is primarily mediated by the carboxyl-terminal tails of both receptors and is highly prevalent in brain regions such as the striatum and hippocampus [PubMed: 12165770]. The complex serves as a critical hub for integrating dopaminergic and glutamatergic signaling, playing a vital role in modulating synaptic plasticity, long-term potentiation (LTP), and cognitive processes. In pathological states, such as schizophrenia, a disruption in this heteromerization is thought to contribute to NMDA receptor hypofunction and cognitive deficits [PubMed: 15148386]. Conversely, in Parkinson's disease, the complex is involved in the development of L-DOPA-induced dyskinesia through aberrant signaling pathways [PubMed: 24713464]. Pharmacological intervention can involve traditional ligands for the constituent receptors or novel 'interfering peptides' that specifically target the protein-protein interface to modulate the complex's stability and function. This target represents a promising avenue for developing more precise neuropsychiatric therapies that minimize the side effects associated with broad receptor activation or inhibition.

Other names

D1R-GluN1 heteromerD1-NMDA receptor complexDopamine D1-NMDA receptor heteromerD1R-NR1 complexD1-GluN1 receptor-receptor interactionDopamine D1 receptor-NMDA receptor complexDRD1-GRIN1 complex

The complex facilitates direct protein-protein interaction between the C-terminal tail of the D1 receptor and the GluN1 subunit of the NMDA receptor, enabling reciprocal allosteric modulation. Drugs targeting this complex act by either activating or inhibiting the individual receptor components or by using interfering peptides to physically decouple the receptors, thereby preventing D1-mediated enhancement of NMDA currents and surface expression [PubMed: 12165770, 16436605].